Dr Ian Krop from Yale Cancer Center in New Haven, Connecticut, and Dr Sara Tolaney from Dana-Farber Cancer Institute in Boston, Massachusetts, summarize major treatment advances over the past year and review relevant ongoing clinical trials for patients with breast cancer.

CME information and select publications here.

Dr Rinath Jeselsohn from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer.

CME information and select publications here.

Dr Rinath M Jeselsohn from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer.

CME information and select publications here.

Dr Rebecca Dent from National Cancer Centre Singapore and Dr Nancy Lin from Dana-Farber Cancer Institute in Boston, Massachusetts, discuss important efficacy and safety data from 2024 related to the management of localized and advanced breast cancers.

CME information and select publications here.

Dr Edward B Garon, Dr Tiffany A Traina, and nurse practitioners Ms Marianne J Davies and Ms Marissa Marti-Smith discuss the role of antibody-drug conjugates in the care of patients with breast and lung cancer and strategies to mitigate and manage treatment-emergent adverse events.

NCPD information and select publications here.

Dr Adam M Brufsky from the University of Pittsburgh discusses first-line treatment selection for patients with HR-positive metastatic breast cancer and preexisting medical conditions.

CME information and select publications here.

Clinical investigators discuss available data guiding the management of HER2-positive, triple-negative and localized breast cancer. 

CME information and select publications here.

Clinical investigators discuss available data guiding the management of hormone receptor-positive metastatic breast cancer.

CME information and select publications here.